JP2006508069A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508069A5 JP2006508069A5 JP2004540421A JP2004540421A JP2006508069A5 JP 2006508069 A5 JP2006508069 A5 JP 2006508069A5 JP 2004540421 A JP2004540421 A JP 2004540421A JP 2004540421 A JP2004540421 A JP 2004540421A JP 2006508069 A5 JP2006508069 A5 JP 2006508069A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- positions
- compound
- independently
- halocarbyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 56
- 239000000203 mixture Substances 0.000 claims 28
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 27
- 229910052799 carbon Inorganic materials 0.000 claims 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 15
- 239000012453 solvate Substances 0.000 claims 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- 125000006657 (C1-C10) hydrocarbyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims 2
- 229950006790 adenosine phosphate Drugs 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000001374 aryl-fused-cycloalkyl group Chemical group 0.000 claims 2
- 125000005841 biaryl group Chemical group 0.000 claims 2
- -1 bicycloalkenyl Chemical group 0.000 claims 2
- 150000001602 bicycloalkyls Chemical group 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 125000005592 polycycloalkyl group Polymers 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 0 Cc1cc(*[C@](C[C@](CN2)c(cc3OC4CCCC4)ccc3OC)C2=O)ccc1 Chemical compound Cc1cc(*[C@](C[C@](CN2)c(cc3OC4CCCC4)ccc3OC)C2=O)ccc1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/263,336 US6770658B2 (en) | 1998-09-09 | 2002-10-01 | Substituted γ-phenyl-Δ-lactams and uses related thereto |
| US10/263,336 | 2002-10-01 | ||
| PCT/CA2003/001506 WO2004031149A1 (en) | 2002-10-01 | 2003-09-30 | Substituted gamma-phenyl-delta-lactams and uses related thereto |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006508069A JP2006508069A (ja) | 2006-03-09 |
| JP2006508069A5 true JP2006508069A5 (enExample) | 2006-11-16 |
| JP4768989B2 JP4768989B2 (ja) | 2011-09-07 |
Family
ID=32068272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004540421A Expired - Fee Related JP4768989B2 (ja) | 2002-10-01 | 2003-09-30 | 置換γ−フェニル−Δ−ラクタムおよびそれらに関連した用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6770658B2 (enExample) |
| EP (1) | EP1551805B1 (enExample) |
| JP (1) | JP4768989B2 (enExample) |
| AU (1) | AU2003271478B2 (enExample) |
| CA (1) | CA2500675C (enExample) |
| CY (1) | CY1114133T1 (enExample) |
| DK (1) | DK1551805T3 (enExample) |
| ES (1) | ES2409333T3 (enExample) |
| MX (1) | MXPA05003547A (enExample) |
| PT (1) | PT1551805E (enExample) |
| SI (1) | SI1551805T1 (enExample) |
| WO (1) | WO2004031149A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770658B2 (en) * | 1998-09-09 | 2004-08-03 | Inflazyme Pharmaceuticals Ltd. | Substituted γ-phenyl-Δ-lactams and uses related thereto |
| US20080051379A1 (en) * | 2004-12-01 | 2008-02-28 | Trustees Of Boston University | Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms |
| WO2006062817A2 (en) * | 2004-12-01 | 2006-06-15 | Boston Medical Center Corporation | Compositions and methods for the treatment of peripheral b-cell neoplasms |
| GB0722769D0 (en) * | 2007-11-21 | 2008-01-02 | Biolipox Ab | New compounds |
| AR065709A1 (es) * | 2007-03-12 | 2009-06-24 | Biolipox Ab | Piperidinonas y composiciones farmaceuticas que las contienen usadas para el tratamiento de la inflamacion. procesos de obtencion. |
| BRPI0916228A2 (pt) * | 2008-07-18 | 2015-11-03 | Dart Neuroscience Llc | métodos e sistemas para avaliação de agentes de memória |
| WO2011114103A1 (en) | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
| CN103038204B (zh) * | 2010-05-31 | 2015-03-04 | 株式会社普利司通 | 含羟基的甲基苯乙烯和引入其的聚合物 |
| JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| EP2753640B1 (en) | 2011-09-08 | 2016-03-09 | Codexis, Inc. | Biocatalysts and methods for the synthesis of substituted lactams |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| US8883857B2 (en) | 2012-12-07 | 2014-11-11 | Baylor College Of Medicine | Small molecule xanthine oxidase inhibitors and methods of use |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| WO2014134201A1 (en) | 2013-02-28 | 2014-09-04 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| WO2014151863A1 (en) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| MA53572A1 (fr) | 2013-06-10 | 2021-10-29 | Amgen Inc | Procédés de production et formes cristallines d'un inhibiteur mdm2 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3607885A (en) | 1968-08-15 | 1971-09-21 | Universal Oil Prod Co | Preparation of lactones such as substituted delta valerolactones |
| US3565904A (en) | 1969-01-31 | 1971-02-23 | Bristol Myers Co | 1,2,3,4-tetrahydro-1-naphthoic acids |
| US3718743A (en) | 1970-11-19 | 1973-02-27 | Merck & Co Inc | 5-phenyl-2-piperidones and 5-phenyl-2-thiopiperidones in compositions and methods for treating pain, fever and inflammation |
| US3814771A (en) | 1970-11-19 | 1974-06-04 | T Shen | 5-phenyl-2-piperidones and 5-phenyl-2-thiopiperidones |
| DK116181A (da) | 1980-04-11 | 1981-10-12 | Hoffmann La Roche | Fremgangsmaade til fremstilling af quinolizidinderivater |
| ZA821888B (en) | 1981-04-01 | 1983-02-23 | Haessle Ab | Novel phenyl-piperidines |
| US4616089A (en) | 1983-08-03 | 1986-10-07 | University Of California | Synthetic anti-inflammatory derivatives of manoalide |
| EP0157364B1 (en) | 1984-04-02 | 1990-09-19 | Daicel Chemical Industries, Ltd. | Separation agent comprising aliphatic or aromatic ester of polysaccharide |
| DE3438839A1 (de) * | 1984-10-19 | 1986-04-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | Pharmazeutische praeparate |
| US4838925A (en) | 1986-04-25 | 1989-06-13 | E. I. Du Pont De Nemours And Company | Heterocyclic acyl sulfonamides |
| US5231192A (en) | 1989-02-24 | 1993-07-27 | Henkel Corporation | Process for the preparation of alpha-alkyl lactones |
| DE4005516A1 (de) | 1989-02-24 | 1990-08-30 | Henkel Corp | Verfahren zur umwandlung (alpha)-acetyl-substituierter lactone in (alpha)-alkyliden-substituierte lactone |
| DE4005515A1 (de) | 1989-02-24 | 1990-08-30 | Henkel Corp | Verfahren zur herstellung von (alpha)-alkyllactonen |
| US5416224A (en) | 1989-02-24 | 1995-05-16 | Henkel Corporation | Process for converting α-acyl-substituted lactones to α-alkylidene-substituted lactones |
| DK0641320T3 (da) | 1991-04-17 | 2001-08-20 | Upjohn Co | Substituerede (S)-3-phenylpiperidinderivater, deres fremstilling og deres anvendelse som dopaminautoreceptorantagonister |
| CA2109618A1 (en) | 1991-05-21 | 1992-11-26 | Edward S. Lipinsky | Degradable cellulose polymers |
| DE4125457A1 (de) | 1991-08-01 | 1993-02-04 | Bayer Ag | Verfahren zur herstellung von n-substituierten lactamen |
| US5234933A (en) | 1991-10-31 | 1993-08-10 | Board Of Governors Of Wayne State University And Vanderbilt University | Cyclic hydroxamic acids |
| JP3101053B2 (ja) | 1992-02-07 | 2000-10-23 | 株式会社共立 | 新規化合物及び該化合物を含有するマツノザイセンチュウ殺線虫剤 |
| IL105168A0 (en) | 1992-04-03 | 1993-07-08 | Lilly Co Eli | Heteroannulation process |
| JPH06157459A (ja) | 1992-11-16 | 1994-06-03 | Eezai Kagaku Kk | ピリジルケトアルコールの製造法 |
| US5478356B1 (en) | 1994-05-10 | 1997-11-18 | Clorox Co | Cyanoimides and compositions useful for bleaching |
| US5629429A (en) | 1995-06-07 | 1997-05-13 | Bristol-Myers Squibb Company | Process for preparing 4-arylamino-benzopyran and related compounds |
| DE19541012A1 (de) | 1995-11-03 | 1997-05-07 | Basf Ag | Verwendung von Oximestern als Aktivatoren für anorganische Perverbindungen |
| WO1997020822A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Quinazolin-2,4-diazirines as npy receptor antagonist |
| DE19603477A1 (de) | 1996-01-31 | 1997-08-07 | Klaus Dr Med Reuter | Tumormittel |
| US6770658B2 (en) * | 1998-09-09 | 2004-08-03 | Inflazyme Pharmaceuticals Ltd. | Substituted γ-phenyl-Δ-lactams and uses related thereto |
| WO2000014083A1 (en) * | 1998-09-09 | 2000-03-16 | Inflazyme Pharmaceuticals Ltd. | SUBSTITUTED η-PHENYL-Δ-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO |
-
2002
- 2002-10-01 US US10/263,336 patent/US6770658B2/en not_active Expired - Lifetime
-
2003
- 2003-09-30 WO PCT/CA2003/001506 patent/WO2004031149A1/en not_active Ceased
- 2003-09-30 CA CA2500675A patent/CA2500675C/en not_active Expired - Fee Related
- 2003-09-30 SI SI200332267T patent/SI1551805T1/sl unknown
- 2003-09-30 EP EP03753187A patent/EP1551805B1/en not_active Expired - Lifetime
- 2003-09-30 ES ES03753187T patent/ES2409333T3/es not_active Expired - Lifetime
- 2003-09-30 AU AU2003271478A patent/AU2003271478B2/en not_active Ceased
- 2003-09-30 PT PT37531878T patent/PT1551805E/pt unknown
- 2003-09-30 JP JP2004540421A patent/JP4768989B2/ja not_active Expired - Fee Related
- 2003-09-30 DK DK03753187.8T patent/DK1551805T3/da active
- 2003-09-30 MX MXPA05003547A patent/MXPA05003547A/es active IP Right Grant
-
2013
- 2013-04-10 CY CY20131100300T patent/CY1114133T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004524308A5 (enExample) | ||
| CA2493765A1 (en) | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | |
| ES2208772T3 (es) | Nuevos compuestos triciclicos y compuestos farmaceuticos que contienen los mismos. | |
| CA2500675A1 (en) | Substituted gamma-phenyl-delta-lactams and uses related thereto | |
| CU23413B7 (es) | Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos | |
| AR041635A1 (es) | Compuestos de 4-piperazinilbencenosulfonilindoles, preparacion de los mismos y composiciones farmaceuticas que los contienen | |
| JP2004526720A5 (enExample) | ||
| ES2173154T3 (es) | Compuestos de naftilo, intermedios, procedimientos y composiciones de los mismos. | |
| JP2005519083A5 (enExample) | ||
| AR035479A1 (es) | Derivados de eteres biarilicos y sus sales, composiciones farmaceuticas que los comprenden y procedimientos para el tratamiento de trastornos o afecciones | |
| CA2466965A1 (en) | Sulphonamide derivatives, their preparation and use as medicaments | |
| WO2021022076A1 (en) | Molecules and methods related to treatment of uncontrolled cellular proliferation | |
| JP2002524456A5 (enExample) | ||
| RU97102362A (ru) | Нейрозащитные производные 3-(пиперидинил-1)-хроман-4,7-диола и 1-(4- гидроксифенил)-2-(пиперидинил-1)-алканола | |
| PT98641A (pt) | Processo para a preparacao de 2-amino-1,2,3,4-tetrahidronaftlalenos 3-aminocromanos substituidos no anel | |
| JP7702384B2 (ja) | Ｖｍａｔ２阻害剤、及びその調製方法、及びその使用 | |
| CA2554550A1 (en) | Hydroisoindoline tachykinin receptor antagonists | |
| UY25519A1 (es) | Procedimiento para preparar antagonista del receptor de vitronectina | |
| JP2007514691A5 (enExample) | ||
| MX2007005709A (es) | Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos. | |
| JP2020533319A5 (enExample) | ||
| CA2483345A1 (en) | Imidazolinylmethyl aralkylsulfonamides | |
| JP2007508301A5 (enExample) | ||
| CO5160341A1 (es) | Oximas e hidrazonas sustituidas como antagonistas de neuroquinina | |
| MX2025008544A (es) | Derivados de 3-(2-(dimetilamino)etil)-1h-indol-4-ilo |